2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update.
Front Pharmacol
; 13: 899633, 2022.
Article
in English
| MEDLINE | ID: covidwho-1952533
ABSTRACT
Treatment choices for the "severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2)" are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the "coronavirus disease 2019 (COVID-19)" patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Journal:
Front Pharmacol
Year:
2022
Document Type:
Article
Affiliation country:
Fphar.2022.899633
Similar
MEDLINE
...
LILACS
LIS